Vutrisiran offers a new lifeline to patients with progressive heart condition
Credit: Unsplash/CC0 Public Domain Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a